TRG 120
Alternative Names: TRG-120Latest Information Update: 09 Jan 2023
At a glance
- Originator Trigone Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Overactive bladder
Most Recent Events
- 27 Dec 2022 Clinical trials in Overactive bladder in Israel (unspecified route), as of December 2022 (Trigone Pharma pipeline, December 2022)
- 27 Dec 2022 Efficacy results from clinical studies of TRG 120 released by Trigone Pharma (Trigone Pharma pipeline, December 2022)